Asset-centric is a term coined by Medicxi founding partner Francesco De Rubertis to describe an investment strategy he pioneered, together with Kevin Johnson and Michele Ollier, in the early years of the 21st Century. The key was focusing investment on a single asset to avoid the problem with pipelines in early-stage biotech companies. While it seemed superficially attractive to hedge against failure of the lead asset by having a second or a third program in the wings, the reality usually turned out differently: when the lead failed and the pivot came, far too frequently the follow-on assets didn’t pass scrutiny. “In short, we ended up developing things we would never have chosen to invest in had they been a lead asset” De Rubertis explains.
Over the next few years, the practice of asset-centric investing was honed through various iterations all designed to counter the inherent progression bias that damages returns in pharmaceutical R&D. Biology is unavoidably complex and always provides a plausible explanation for any failure, allowing managers with a natural aversion to crystalising losses to keep trying. Maybe it was the wrong patient population? The wrong dose? Not long enough treatment? The wrong end-point? Of course, Occam’s razor suggests the simplest explanation is likely to be right: the drug just doesn’t work well enough – but many millions are often burnt before the inevitable conclusion is reached.
One of the principal causes of progression bias is the creation of infrastructure – if you have a team of employees, a lease on a building and so forth it can be painful to call a halt even if the enthusiasm is draining away. As long as there is a plausible route forward, and there nearly always is, then further investment become almost inevitable – a phenomenon often described as “the hand in the mangle” (referencing a long-defunct apparatus comprised of two rollers used to squeeze water from clothes during laundry, which, if it caught your hand, it was almost impossible to escape from without a painful injury).
Asset-centric investment used out-sourced infrastructure to reduce the drag of progression-seeking behaviours, and over a decade delivered the ultimate asset-centric company: the zero-person biotech. Capital was dripped in slowly, so none was “trapped” inside a company that had begun to deviate from a stellar trajectory. Over the years, Medicxi switched the progression heuristic from “nothing has yet killed the opportunity” to “we are still excited and want to further back the opportunity”. It sounds subtle, but the impact is enormous.
Other benefits became apparent, as much by chance as by …
Valuing biotech assets, whether an early-stage private investment …More
This week, Eleven Biotherapeutics ($EBIO) announced the failure …More
There has been much written about the proposed …More
With the details from the DEMAND-III study, the …More
Once upon a time, getting a drug approved …More
As biotech companies queue up like lemmings on …More
In 2010, DrugBaron declared the death of incremental …More
Index Ventures have announced the completion of an …More
The acquisition of Pearl Therapeutics for up to …More
The Cambridge Partnership is the only professional services company in the UK exclusively dedicated to supporting companies in the biotechnology industry. We specialize in providing a “one-stop shop” for accountancy, company secretarial, IP management and admin services. The Cambridge Partnership was founded in 2012 to fill a gap. Running a biotechnology company has little …